Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2019.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.
Am J Hematol
September 2025
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma with poor outcomes using standard chemotherapy. In this multi-institutional retrospective study, we analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024, with treatment including conventional cytotoxic regimens in frontline and biologically informed and nonchemotherapy-based strategies in the relapsed setting. Ninety-two percent of patients received frontline anthracycline-based chemotherapy; 43% received intensified regimens, and 15% underwent upfront autologous stem cell transplantation (ASCT).
View Article and Find Full Text PDFFollicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany.
Ann Hematol
September 2025
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Contemporary information on epidemiology, healthcare resource utilization (HCRU), costs and clinical outcomes in routine care is essential for value-based decision-making. However, such information remains limited for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in Germany. This study addresses these gaps.
View Article and Find Full Text PDFTreatment of Diffuse Large B-cell Lymphoma Progressing or Relapsing after Chimeric Antigen Receptor T-cell Therapy.
Transplant Cell Ther
August 2025
Research Methodology and Biostatistics Core, Office of Research Morsani College of Medicine, University of South Florida, Tampa, Florida. Electronic address:
There is no established standard treatment for diffuse large B-cell lymphoma (DLBCL) progressing or relapsing after chimeric antigen receptor T-cell therapy (CAR T-cell). While enrollment in clinical trials is ideal, unfortunately, many are not eligible to participate. Various treatment modalities exist with heterogeneous efficacies.
View Article and Find Full Text PDFGenetic background of Richter transformation of atypical chronic lymphocytic leukemia to diffuse large B-cell lymphoma - a case study.
J Appl Genet
August 2025
Department of Hematology and Bone Transplantation, University of Medical Sciences, Poznań, Poland.
Atypical chronic lymphocytic leukemia (aCLL) is an indolent lymphoproliferative neoplasm derived from CD19-positive and CD5 or CD23-negative B cells. This paper presents the results of whole genome sequencing (WGS) of lymphoma cells collected from a 29-year-old woman initially diagnosed with aCLL and successfully treated with fludarabine, cyclophosphamide, and rituximab. Eight years later, due to disease progression, she was treated with ibrutinib.
View Article and Find Full Text PDFUnlabelled: Chimeric antigen receptor (CAR) T-cell therapies are approved as second-line (2L) or later therapy for diffuse large B-cell lymphoma (DLBCL). Recently, bispecific T-cell antibodies (BsAbs) have been approved as third-line (3L) treatments. The cost-effectiveness of different treatment sequences is unknown.
View Article and Find Full Text PDF